Redhill Biopharma Stock Performance
RDHL Stock | USD 0.42 0.01 2.35% |
The company holds a Beta of -0.0816, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Redhill Biopharma are expected to decrease at a much lower rate. During the bear market, Redhill Biopharma is likely to outperform the market. Redhill Biopharma has an expected return of -0.67%. Please make sure to check Redhill Biopharma treynor ratio and the relationship between the skewness and period momentum indicator , to decide if Redhill Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Redhill Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical indicators remain quite persistent which may send shares a bit higher in May 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:40 | Last Split Date 2023-03-23 |
1 | RedHill Biopharma Ltd. Short Interest Update - AmericanBankingNEWS | 02/28/2024 |
2 | BIO-Europe Spring 2024 is Only a Few Days Away | 03/07/2024 |
3 | RedHill Announces New USPTO Patent Covering Talicia Through 2034 | 03/11/2024 |
4 | RedHill Biopharma Share Capital Increase Approved - TipRanks.com - TipRanks | 03/21/2024 |
5 | RedHill Biopharma looks to raise 1.25M in a direct offering of securities | 04/02/2024 |
6 | RedHill GAAP EPS of 0.01, revenue of 6.53M | 04/08/2024 |
7 | RedHill Biopharma Full Year 2023 Earnings EPS US4.00 | 04/10/2024 |
8 | AscellaHealth Expands Executive Team Industry Veterans Lead Development and Implementation of End-to-End Payer Solutions and Pharmacy Operations to Control Spec... | 04/11/2024 |
Begin Period Cash Flow | 36 M |
Redhill |
Redhill Biopharma Relative Risk vs. Return Landscape
If you would invest 68.00 in Redhill Biopharma on January 26, 2024 and sell it today you would lose (26.01) from holding Redhill Biopharma or give up 38.25% of portfolio value over 90 days. Redhill Biopharma is currently does not generate positive expected returns and assumes 4.6387% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Redhill, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Redhill Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Redhill Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Redhill Biopharma, and traders can use it to determine the average amount a Redhill Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1447
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | RDHL |
Estimated Market Risk
4.64 actual daily | 41 59% of assets are more volatile |
Expected Return
-0.67 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Redhill Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Redhill Biopharma by adding Redhill Biopharma to a well-diversified portfolio.
Redhill Biopharma Fundamentals Growth
Redhill Stock prices reflect investors' perceptions of the future prospects and financial health of Redhill Biopharma, and Redhill Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Redhill Stock performance.
Return On Equity | -8.84 | ||||
Return On Asset | -0.16 | ||||
Profit Margin | 3.66 % | ||||
Operating Margin | (10.61) % | ||||
Current Valuation | 3.36 B | ||||
Shares Outstanding | 31.87 M | ||||
Price To Earning | (3.67) X | ||||
Price To Book | 6.55 X | ||||
Price To Sales | 2.08 X | ||||
Revenue | 6.51 M | ||||
Gross Profit | 45.25 M | ||||
EBITDA | (29.37 M) | ||||
Net Income | 23.85 M | ||||
Cash And Equivalents | 28.86 M | ||||
Cash Per Share | 0.55 X | ||||
Total Debt | 1.17 M | ||||
Debt To Equity | 9.89 % | ||||
Current Ratio | 0.98 X | ||||
Book Value Per Share | 0.10 X | ||||
Cash Flow From Operations | (35.73 M) | ||||
Earnings Per Share | 4.00 X | ||||
Market Capitalization | 13.63 M | ||||
Total Asset | 23.05 M | ||||
Retained Earnings | (407.74 M) | ||||
Working Capital | (3.1 M) | ||||
Current Asset | 60.51 M | ||||
Current Liabilities | 5.51 M | ||||
About Redhill Biopharma Performance
To evaluate Redhill Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Redhill Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Redhill Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Redhill Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Redhill's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 602.93 | 633.07 | |
Return On Tangible Assets | 1.37 | 1.44 | |
Return On Capital Employed | (8.24) | (7.83) | |
Return On Assets | 1.04 | 1.09 | |
Return On Equity | 11.56 | 12.14 |
Things to note about Redhill Biopharma performance evaluation
Checking the ongoing alerts about Redhill Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Redhill Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Redhill Biopharma generated a negative expected return over the last 90 days | |
Redhill Biopharma has some characteristics of a very speculative penny stock | |
Redhill Biopharma has high historical volatility and very poor performance | |
Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
The company currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Redhill Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Redhill Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Redhill Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Redhill to invest in growth at high rates of return. When we think about Redhill Biopharma's use of debt, we should always consider it together with cash and equity. | |
Redhill Biopharma currently holds about 28.86 M in cash with (35.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Redhill Biopharma has a poor financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: AscellaHealth Expands Executive Team Industry Veterans Lead Development and Implementation of End-to-End Payer Solutions and Pharmacy Operations to Control Specialty Spend |
- Analyzing Redhill Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Redhill Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Redhill Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Redhill Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Redhill Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Redhill Biopharma's stock. These opinions can provide insight into Redhill Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.